Resistance models may quantify the ability of the landscape to impede species' movement and represent suitable habitats. Moreover, the performance of resistance models parameterized by land-use/land cover attributes evidence that the integrity of the environments subject to urban sprawl is poorly understood. In this sense, the study assumed we could identify the forest functional connectivity in a landscape considering the disparity in the landscape mosaic. In this context, we sought to develop a landscape resistance index through structural equation modeling (SEM), supported by the criteria of heat emission, biomass, and anthropogenic barriers, obtained by remote sensing, called observed variables. The landscape studied in the Green Belt Biosphere Reserve of São Paulo has significant remnants of the Atlantic Forest, a biodiversity hotspot. However, our results indicated criteria variability in the landscape modeled through the SEM, obtaining a significant adjustment of the landscape resistance index, with comparative fit index (CFI) of 1.00 and root mean square error of approximation (RMSEA) of 0.00. The index reflects the resistance levels of the land use/land cover, expressed by the class interval, ranging from 0% (1.73) to 100% (493.88), with the highest values associated with the anthropized uses and forest isolation. Thus, our index based on environmental attributes reflects the structure of functional forest connectivity and offers a framework to design forest corridors across landscapes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10661-023-11749-x | DOI Listing |
BMC Cancer
January 2025
Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Peking, Beijing, 100023, People's Republic of China.
Background: Pancreatic cancer is a highly aggressive neoplasm characterized by poor diagnosis. Amino acids play a prominent role in the occurrence and progression of pancreatic cancer as essential building blocks for protein synthesis and key regulators of cellular metabolism. Understanding the interplay between pancreatic cancer and amino acid metabolism offers potential avenues for improving patient clinical outcomes.
View Article and Find Full Text PDFNat Med
January 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by KRAS exon 2 mutations. Most patients with PDAC present with advanced disease and are treated with cytotoxic therapy. Genomic biomarkers prognostic of disease outcomes have been challenging to identify.
View Article and Find Full Text PDFCurr Oncol Rep
January 2025
Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Chiba, Japan.
Purpose Of Review: Human epidermal growth factor receptor 2 (HER2) is a critical target in advanced gastric cancer (AGC). This review highlights the current treatment landscape, lessons learned from past clinical trials, and prospects for future treatment strategies for HER2-positive AGC.
Recent Findings: Trastuzumab had been the standard treatment for HER2-positive AGC for a decade, and subsequently, trastuzumab deruxtecan, an antibody-drug conjugate (ADC), emerged with an impressive response.
Cell Rep
January 2025
The Brain Tumor Translational Laboratory, Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA. Electronic address:
The sub-ventricular zone (SVZ) is the most well-characterized neurogenic area in the mammalian brain. We previously showed that in 65% of patients with glioblastoma (GBM), the SVZ is a reservoir of cancer stem-like cells that contribute to treatment resistance and the emergence of recurrence. Here, we build a single-nucleus RNA-sequencing-based microenvironment landscape of the tumor mass and the SVZ of 15 patients and two histologically normal SVZ samples as controls.
View Article and Find Full Text PDFFront Oncol
December 2024
Wellington Blood and Cancer Centre, Te Whatu Ora Capital, Wellington, New Zealand.
Immunotherapy has revolutionised the treatment landscape of non-small cell lung cancer (NSCLC), significantly improving survival outcomes and offering renewed hope to patients with advanced disease. However, the majority of patients experience limited long-term benefits from immune checkpoint inhibition (ICI) due to the development of primary or acquired immunotherapy resistance. Accurate predictive biomarkers for immunotherapy resistance are essential for individualising treatment strategies, improving survival outcomes, and minimising potential treatment-related harm.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!